The AmpliChip® CYP450 test and response to treatment in schizophrenia and obsessive compulsive disorder: A pilot study and focus on cases with abnormal CYP2D6 drug metabolism

Genetic Testing and Molecular Biomarkers

Volumn 16, Issue 8, 2012, Pages 897-903

  Müller, Daniel J ^a   Brandl, Eva J ^a   Hwang, Rudi ^a   Tiwari, Arun K ^a   Sturgess, Jessica E ^a   Zai, Clement C ^a   Lieberman, Jeffrey A ^b   Kennedy, James L ^a   Richter, Margaret A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; SERTRALINE; TRIFLUOPERAZINE;

ADULT; ARTICLE; DRUG METABOLISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSESSIVE COMPULSIVE DISORDER; PILOT STUDY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VALIDATION STUDY; XEROSTOMIA;

ADULT; COHORT STUDIES; CYTOCHROME P-450 CYP2D6; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PILOT PROJECTS; SCHIZOPHRENIA;

EID: 84865681276     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2011.0327     Document Type: Article

References (57)

1. Arranz MJ, Dawson E, Shaikh S et al. (1995) Cytochrome P4502D6 genotype does not determine response to clozapine. Br J Clin Pharmacol 39:417-420.
2. Basile VS, Masellis M, Potkin SG, et al. (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11:2517-2530.
3. Baumann P, Barbe R, Vabre-Bogdalova A, et al. (2006) Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. J Clin Psychopharmacol 26:679-681.
4. Bork JA, Rogers T, Wedlund PJ, et al. (1999) A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A. J Clin Psychiatry 60:469-476.
5. Brockmoller J, Kirchheiner J, Schmider J, et al. (2002) The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 72:438-452.
6. *6 polymorphisms and antipsychotic-induced extrapyramidal side-effects in patients receiving antipsychotic therapy. Clin Exp Pharmacol Physiol 35:807-811.
7. de Leon J (2007). The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 27:241-245.
8. de Leon J. (2008) The potential of genotyping. Science 321:769.
9. de Leon J, Armstrong SC, Cozza KL (2006a) Clinical Guidelines for Psychiatrists for the Use of Pharmacogenetic Testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47:75-85.
10. de Leon J, Susce MT, Murray-Carmichael E (2006b) The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 10:135-151.
11. de Leon J, Susce MT, Pan RM, et al. (2005) The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 66:15-27.
12. de Leon J, Susce MT, Pan RM, et al. (2007) A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 40:93-102.
13. de Leon J, Wynn G, Sandson NB (2010) The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 51:80-88.
14. Dunbar L, Butler R, Wheeler A, et al. (2012) Clinician experiences of employing the AmpliChip (R) CYP450 test in routine psychiatric practice. J Psychopharmacol 26:390-397.
15. Ellingrod VL, Miller D, Schultz SK, et al. (2002) CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet 12:55-58.
16. Fleeman N, Dundar Y, Dickson R et al. (2011) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J 11:1-14.
17. Fleeman N, McLeod C, Bagust A et al. (2010) The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. Health Technol Assess 14:1-157, iii.
18. Fu Y, Fan CH, Deng HH et al. (2006) Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol Sin 27:328-332.
19. Guzey C, Aamo T, Spigset O (2000) Risperidone metabolism and the impact of being a cytochrome P450 2D6 ultrarapid metabolizer. J Clin Psychiatry 61:600-601.
20. Hendset M, Haslemo T, Rudberg I, et al. (2006) The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs. Pharmacopsychiatry 39:121-127.
21. Hendset M, Molden E, Refsum H, et al. (2009) Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol 29:537-541.
22. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
23. Jenike MA (2004) Clinical practice. Obsessive-compulsive disorder. N Engl J Med 350:259-265.
24. Johnson M, Markham-Abedi C, Susce MT, et al. (2006) A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment. CNS Spectr 11:757-760.
25. Jovanović N, Božina N, Lovrić M, et al. (2010) The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naïve patients with first-episode schizophrenia treated with risperidone. Eur J Clin Pharmacol 66:1109-1117.
26. Kakihara S, Yoshimura R, Shinkai K et al. (2005) Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6. Int Clin Psychopharmacol 20:71-78.
27. Katsanis SH, Javitt G, Hudson K (2008) Public health. A case study of personalized medicine. Science 320:53-54.
28. Kirchheiner J, Lang U, Stamm T, et al. (2006) Association of CYP2D6 genotypes and personality traits in healthy individuals. J Clin Psychopharmacol 26:440-442.
29. Kirchheiner J, Nickchen K, Bauer M, et al. (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9:442-473.
30. Kirchheiner J, Seeringer A, Godoy AL et al. (2011) CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatry 16:237, 333-341.
31. Kobylecki CJ, Jakobsen KD, Hansen T, et al. (2009) CYP2D6 genotype predicts antipsychotic side effects in schizophrenia inpatients: a retrospective matched case-control study. Neuropsychobiology 59:222-226.
32. Kohnke MD, Griese EU, Stosser D, et al. (2002) Cytochrome P450 2D6 deficiency and its clinical relevance in a patient treated with risperidone. Pharmacopsychiatry 35:116-118.
33. Lahiri DK, Nurnberger JI, Jr (1991) A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19:5444.
34. Laika B, Leucht S, Heres S, et al. (2009) Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening? Pharmacogenomics J 9:395-403.
35. Lane HY, Liu YC, Huang CL et al. (2006) Risperidone-related weight gain: genetic and nongenetic predictors. J Clin Psychopharmacol 26:128-134.
36. Llerena A, Berecz R, Dorado P, et al. (2004) QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol 18:189-193.
37. *17. Br J Clin Pharmacol 69:222-230.
38. Locatelli I, Kastelic M, Koprivsek J et al. (2010) A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur J Pharm Sci 41:289-298.
39. Lohmann PL, Bagli M, Krauss H et al. (2003) CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry 36:73-78.
40. Müller DJ, Klempan TA, De Luca V, et al. (2005) The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. Neurosci Lett 379:81-89.
41. Patsopoulos NA, Ntzani EE, Zintzaras E, et al. (2005) CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis. Pharmacogenet Genomics 15:151-158.
42. Peñas-LLedó EM, Dorado P, Pacheco R, et al. (2009) Relation between CYP2D6 genotype, personality, neurocognition and overall psychopathology in healthy volunteers. Pharmacogenomics 10:1111-1120.
43. Plesnicar BK, Zalar B, Breskvar K, et al. (2006) The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 20:829-833.
44. Porcelli S, Drago A, Fabbri C, et al. (2011) Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 36:87-113.
45. Rau T, Wohlleben G, Wuttke H, et al. (2004) CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther 75:386-393.
46. Riedel M, Schwarz MJ, Strassnig M et al. (2005) Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 255:261-268.
47. Roche Diagnostics NA (2009) AmpliChip. Available at http://molecular. roche.com/assays/Pages/AmpliChipCYP450Test.aspx.
48. Rodríguez-Antona C, Gurwitz D, de Leon J et al. (2009) CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies. Pharmacogenomics 10:685-699.
49. Sallee FR, De Vane CL, Ferrell RE (2000) Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. J Child Adolesc Psychopharmacol 10:27-34.
50. Shetti CN, Reddy YC, Kandavel T et al. (2005) Clinical predictors of drug nonresponse in obsessive-compulsive disorder. J Clin Psychiatry 66:1517-1523.
51. Thakur M, Grossman I, McCrory DC et al. (2007) Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med 9:826-835.
52. Tiwari AK, Deshpande SN, Rao AR et al. (2005) Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr Res 75:21-26.
53. Tsai HT, Caroff SN, Miller del D et al. (2010) A candidate gene study of Tardive dyskinesia in the CATIE schizophrenia trial. Am J Med Genet B Neuropsychiatr Genet 153 B: 336-340.
54. Van Nieuwerburgh FC, Denys DA, Westenberg HG, et al. (2009) Response to serotonin reuptake inhibitors in OCD is not influenced by common CYP2D6 polymorphisms. Int J Psychiatry Clin Pract 13:345-348.
55. Vetti HH, Molven A, Eliassen AK, et al. (2010) Is pharmacogenetic CYP2D6 testing useful? Tidsskr Nor Laegeforen 130:2224-2228.
56. Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174-183.
57. Zhang JP, Malhotra AK (2011) Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7:9-37.